Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 5.6 %

EGRX stock opened at $0.95 on Thursday. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $9.00. The business’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $3.54.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 2,630 shares during the period. Mackenzie Financial Corp acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $65,000. Fidelis Capital Partners LLC acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals during the second quarter worth $76,000. 85.36% of the stock is owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.